Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
8.64
+0.33 (3.97%)
Jun 5, 2025, 4:00 PM - Market closed
Surrozen Revenue
Surrozen had revenue of $983.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $11.64M. In the year 2024, Surrozen had annual revenue of $10.66M.
Revenue (ttm)
$11.64M
Revenue Growth
n/a
P/S Ratio
2.37
Revenue / Employee
$283,854
Employees
41
Market Cap
73.39M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SRZN News
- 22 days ago - Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway - GlobeNewsWire
- 27 days ago - Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases - GlobeNewsWire
- 7 months ago - Surrozen to Present at Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 7 months ago - Surrozen Provides Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 7 months ago - Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 9 months ago - Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration - GlobeNewsWire